A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 136 → 131 locations
  2. Study sites: 137 to 136
    • Eligibility criteria expanded, about 10 words
  3. Study sites: 138 to 137v22
  4. Site details revised at 5 of 138 sitesv21
  5. Study sites: 136 to 138v20
  6. Trial sites expanded: 133 → 136 locationsv19
  7. Study sites: 132 to 133v18
  8. Site details revised at 5 of 132 sitesv17
  9. Site details revised at 13 of 132 sitesv16
  10. Site details revised at 8 of 132 sitesv15
  11. Site details revised at 10 of 132 sitesv14
  12. Study sites: 131 to 132v13
  13. Study sites: 129 to 131
    • Eligibility criteria shortened, about 12 words
    • Secondary endpoints: details revised at 1 of 9 entries
    v12
  14. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2026 to Feb 5, 2026
    • Study sites revised (129)
    v11
  15. Study sites: 128 to 129v10
  16. Study sites: 130 to 128v9
  17. Study sites: 129 to 130v8
  18. Site contacts updated at 2 of 129 sitesv7
  19. Study sites: 130 to 129v6
  20. Study sites: 131 to 130v5
  21. Site details revised at 1 of 131 sitesv4
  22. Study sites: 132 to 131v3
  23. Eligibility criteria expanded, about 8 wordsv2
  24. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Type 1 Diabetes
888 trials monitored
See 39 trials at risk
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Trial Details
NCT Number NCT07222332
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Diabetes Mellitus, Type 1
Related terms Diabetes Mellitus, Type 1
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov